Source: Cure Today articles
Some patients are at higher risk of infection, so it’s critical that they keep their care team up to date on any symptoms.
Recent Content
- Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
- Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
- Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
- Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
- IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
- Combination induces durable responses in advanced multiple myeloma
- Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
- Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
- Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
- Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials